Bao Zhang, Lim Shuhui, Liao Wupeng, Lin Yuzhi, Thiemermann Christoph, Leung Bernard P, Wong W S Fred
Department of Pharmacology, Yong Loo Lin School of Medicine, Singapore.
Am J Respir Crit Care Med. 2007 Sep 1;176(5):431-8. doi: 10.1164/rccm.200609-1292OC. Epub 2007 Jun 7.
Persistent activation of nuclear factor-kappaB has been associated with the development of asthma. Glycogen synthase kinase-3beta is known to regulate the activity of nuclear factor-kappaB.
We hypothesized that inhibition of glycogen synthase kinase-3beta may have anti-inflammatory effects in allergic asthma.
BALB/c mice sensitized and challenged with ovalbumin developed airway inflammation. Bronchoalveolar lavage fluid was assessed for total and differential cell counts, and for cytokine and chemokine levels. Lung tissues were examined for cell infiltration and mucus hypersecretion, and for the expression of inflammatory biomarkers. Serum immunoglobulin E levels were determined by enzyme-linked immunosorbant assay. Airway hyperresponsiveness was monitored by direct airway resistance analysis.
Intravenous administration of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a selective glycogen synthase kinase-3beta inhibitor, significantly inhibited ovalbumin-induced increases in total cell counts, eosinophil counts, and IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner. TDZD-8 substantially reduced the serum levels of ovalbumin-specific IgE. Histologic studies showed that TDZD-8 dramatically inhibited ovalbumin-induced lung tissue eosinophilia and airway mucus production. TDZD-8 also markedly suppressed ovalbumin-induced mRNA expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, Muc5ac, and three members of the chitinase family (acidic mammalian chitinase, Ym1, and Ym2). In addition, TDZD-8 significantly reduced ovalbumin-induced airway hyperresponsiveness to inhaled methacholine. Western blot analysis of whole lung lysates revealed that TDZD-8 markedly attenuated the phosphorylation of the nuclear factor-kappaB subunit p65 from ovalbumin-challenged mice.
Our findings suggest that inhibition of glycogen synthase kinase-3beta may provide a novel means for the treatment of allergic airway inflammation.
核因子-κB的持续激活与哮喘的发生发展有关。已知糖原合酶激酶-3β可调节核因子-κB的活性。
我们假设抑制糖原合酶激酶-3β可能对过敏性哮喘具有抗炎作用。
用卵清蛋白致敏和激发的BALB/c小鼠发生气道炎症。评估支气管肺泡灌洗液中的总细胞计数和分类细胞计数,以及细胞因子和趋化因子水平。检查肺组织中的细胞浸润和黏液分泌过多情况,以及炎症生物标志物的表达。通过酶联免疫吸附测定法测定血清免疫球蛋白E水平。通过直接气道阻力分析监测气道高反应性。
静脉注射选择性糖原合酶激酶-3β抑制剂4-苄基-2-甲基-1,2,4-噻二唑烷-3,5-二酮(TDZD-8),以剂量依赖的方式显著抑制卵清蛋白诱导的支气管肺泡灌洗液中总细胞计数、嗜酸性粒细胞计数以及IL-5、IL-13和嗜酸性粒细胞趋化因子水平的升高。TDZD-8显著降低了卵清蛋白特异性IgE的血清水平。组织学研究表明,TDZD-8显著抑制卵清蛋白诱导的肺组织嗜酸性粒细胞增多和气道黏液产生。TDZD-8还明显抑制了卵清蛋白诱导的细胞间黏附分子-1、血管细胞黏附分子-1、Muc5ac以及几丁质酶家族的三个成员(酸性哺乳动物几丁质酶、Ym1和Ym2)的mRNA表达。此外,TDZD-8显著降低了卵清蛋白诱导的气道对吸入乙酰甲胆碱的高反应性。对全肺裂解物进行的蛋白质印迹分析显示,TDZD-8显著减弱了卵清蛋白激发小鼠的核因子-κB亚基p65的磷酸化。
我们的研究结果表明,抑制糖原合酶激酶-3β可能为治疗过敏性气道炎症提供一种新方法。